Clinical

Dataset Information

0

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer


ABSTRACT: This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Adenocarcinoma,Colorectal Cancer,Colo-rectal Cancer,Rectal Cancer,Liver Neoplasms,Colorectal Carcinoma,Neoplasm Metastasis,Rectal Neoplasms,Liver Metastases,Neoplasms, Second Primary,Colon Cancer,Liver Metastasis Colon Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Colonic Neoplasms

PROVIDER: 2317731 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2010-03-18 | GSE18392 | GEO
2010-03-18 | E-GEOD-18392 | biostudies-arrayexpress
| 2393378 | ecrin-mdr-crc
| 2262423 | ecrin-mdr-crc
| 66303 | ecrin-mdr-crc
2024-09-16 | GSE276920 | GEO
2024-09-16 | GSE276916 | GEO
2024-01-27 | GSE254054 | GEO
2016-04-27 | GSE80677 | GEO
| 2256236 | ecrin-mdr-crc